Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2026 04:17 ET | Source: Research and Markets

Global Needle-Free Diabetes Care Market Set to Reach USD 19.88 Billion by 2032, Revolutionizing Chronic Disease Management

Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Needle Free Diabetes Care Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.The Needle Free Diabetes Care Market...
January 12, 2026 08:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing...
December 09, 2025 18:35 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif.,...
December 05, 2025 07:49 ET | Source: Research and Markets

Europe $7.4 Bn Insulin Pen Market Opportunities, Growth Drivers, Industry Trend Analysis, and Forecasts 2025-2034

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "Europe Insulin Pen Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...
December 05, 2025 07:47 ET | Source: Research and Markets

North America $9.2 Bn Insulin Pen Market Opportunities, Growth Drivers, Industry Trend Analysis, and Forecasts 2025-2034

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "North America Insulin Pen Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...
December 05, 2025 07:46 ET | Source: Research and Markets

U.S. $8 Bn Insulin Pen Market Opportunities, Growth Drivers, Industry Trend Analysis, and Forecasts 2024-2034

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "U.S. Insulin Pen Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...
December 01, 2025 11:10 ET | Source: Research and Markets

European Association for the Study of Diabetes (EASD) Annual Meeting Highlights 2025: Advancements in GLP-1RAs for Diabetes, Cardiovascular Treatments, and Therapies for Resistant Hypertension

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "European Association for the Study of Diabetes (EASD): Annual Meeting 2025 Highlights" report has been added to ResearchAndMarkets.com's offering.The...
November 13, 2025 11:09 ET | Source: Research and Markets

Self-Monitoring Blood Glucose (SMBG) Devices Market Outlook Report 2025-2034: Opportunities in Integrating with Mobile Apps for Real-time Tracking, Embracing User-friendly Designs

Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The "Self-Monitoring Blood Glucose (Smbg) Devices Market Outlook 2025-2034: Market Share, and Growth Analysis" report has been added to ...
November 05, 2025 07:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A...
November 04, 2025 16:05 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”)...